CN114646711B - 一种羟甲基苯妥英相关杂质的检测方法 - Google Patents
一种羟甲基苯妥英相关杂质的检测方法 Download PDFInfo
- Publication number
- CN114646711B CN114646711B CN202011521088.3A CN202011521088A CN114646711B CN 114646711 B CN114646711 B CN 114646711B CN 202011521088 A CN202011521088 A CN 202011521088A CN 114646711 B CN114646711 B CN 114646711B
- Authority
- CN
- China
- Prior art keywords
- phenytoin
- hydroxymethylphenytoin
- high performance
- performance liquid
- liquid chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002036 phenytoin Drugs 0.000 title claims abstract description 106
- -1 hydroxymethyl phenytoin Chemical compound 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 42
- 239000012535 impurity Substances 0.000 title claims abstract description 31
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims abstract description 61
- 238000001514 detection method Methods 0.000 claims abstract description 58
- 239000012488 sample solution Substances 0.000 claims abstract description 55
- 239000000523 sample Substances 0.000 claims abstract description 48
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 36
- 230000002378 acidificating effect Effects 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000003480 eluent Substances 0.000 claims abstract description 15
- 238000010828 elution Methods 0.000 claims abstract description 13
- 238000000926 separation method Methods 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000003993 interaction Effects 0.000 claims abstract description 7
- 238000013375 chromatographic separation Methods 0.000 claims abstract description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 96
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 40
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 12
- 229910052708 sodium Inorganic materials 0.000 abstract description 12
- 239000011734 sodium Substances 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 7
- 238000003908 quality control method Methods 0.000 abstract description 4
- 239000003085 diluting agent Substances 0.000 description 45
- 238000007865 diluting Methods 0.000 description 26
- 230000014759 maintenance of location Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 16
- 239000012490 blank solution Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 5
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000105 evaporative light scattering detection Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GQPXYJNXTAFDLT-UHFFFAOYSA-L disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Chemical compound [Na+].[Na+].O=C1N(COP([O-])(=O)[O-])C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 GQPXYJNXTAFDLT-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960001934 fosphenytoin sodium Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/78—Detectors specially adapted therefor using more than one detector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011521088.3A CN114646711B (zh) | 2020-12-21 | 2020-12-21 | 一种羟甲基苯妥英相关杂质的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011521088.3A CN114646711B (zh) | 2020-12-21 | 2020-12-21 | 一种羟甲基苯妥英相关杂质的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114646711A CN114646711A (zh) | 2022-06-21 |
CN114646711B true CN114646711B (zh) | 2023-06-23 |
Family
ID=81990953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011521088.3A Active CN114646711B (zh) | 2020-12-21 | 2020-12-21 | 一种羟甲基苯妥英相关杂质的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114646711B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101105479A (zh) * | 2007-08-10 | 2008-01-16 | 复旦大学附属华山医院 | 一种测定人血浆中苯妥英及其前体药物和代谢物的方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH696765A5 (de) * | 2004-06-02 | 2007-11-30 | Cilag Ltd | Verfahren zur Herstellung von Natrium-fosphenytoin. |
US20160349221A1 (en) * | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device |
CN106279279B (zh) * | 2016-08-15 | 2018-06-01 | 广安凯特制药有限公司 | 一种磷苯妥英钠的制备工艺 |
CN107478747B (zh) * | 2017-05-10 | 2019-11-08 | 山东省公安厅 | 血液中未知毒物的液相色谱-质谱筛查方法 |
-
2020
- 2020-12-21 CN CN202011521088.3A patent/CN114646711B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101105479A (zh) * | 2007-08-10 | 2008-01-16 | 复旦大学附属华山医院 | 一种测定人血浆中苯妥英及其前体药物和代谢物的方法 |
Non-Patent Citations (1)
Title |
---|
磷苯妥英钠合成工艺的研究;韩莹 等;天津理工大学学报;第26卷(第02期);第61-62页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114646711A (zh) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Giera et al. | Recent advancements in the LC-and GC-based analysis of malondialdehyde (MDA): a brief overview | |
Greco et al. | Microdialysate analysis of monoamine neurotransmitters—a versatile and sensitive LC–MS/MS method | |
Zhang et al. | Measurement of neurotransmitters from extracellular fluid in brain by in vivo microdialysis and chromatography–mass spectrometry | |
Lagerborg et al. | High-throughput measure of bioactive lipids using non-targeted mass spectrometry | |
CN110849980A (zh) | 一种l-丙氨酸异丙酯中对映异构体含量的检测方法 | |
Rangiah et al. | Comprehensive analysis of neurotransmitters from regenerating planarian extract using an ultrahigh‐performance liquid chromatography/mass spectrometry/selected reaction monitoring method | |
Świt et al. | Spectroscopic Determination of Acetylcholine (ACh): A Representative Review | |
CN114646711B (zh) | 一种羟甲基苯妥英相关杂质的检测方法 | |
CN114778743B (zh) | L-脯氨酸中痕量手性异构体d-脯氨酸的检测方法 | |
CN117191970A (zh) | 一种同时检测n-溴代丁二酰亚胺和n-氯代丁二酰亚胺的方法 | |
Feng et al. | Determination of adenosine phosphates in mouse myocardium tissue by HPLC with UV detection and using porous graphite carbon column | |
Oflu et al. | Combination of quadrupole isotope dilution mass spectrometry with simultaneous derivatization and spray assisted droplet formation-liquid phase microextraction for the determination of methamphetamine in human urine and serum samples by gas chromatography mass spectrometry | |
Yoshitake et al. | Liquid chromatography method for detecting native fluorescent bioamines in urine using post-column derivatization and intramolecular FRET detection | |
CN110954629A (zh) | 一种呋塞米中糠胺含量测定的控制方法 | |
CN108794369B (zh) | 含醛基的手性胺识别探针及其制备方法和应用 | |
Tobolkina et al. | Challenges in ESI-MS-based untargeted metabolomics | |
CN110551143A (zh) | 一种新型的测定生物样品中醛酮化合物的衍生化方法 | |
CN114324703B (zh) | 一种同时检测多种氨基酸的方法 | |
CN112630314B (zh) | 一种l-丙氨酸异丙酯盐酸盐与其对映异构体的分离方法 | |
CN110095554B (zh) | 高效液相色谱分析米力农有关物质的方法 | |
Ozyurt et al. | Determination of 3-nitrotyrosine in food protein suspensions | |
CN109765316B (zh) | 一种从药物中检测右乙拉西坦的方法 | |
Fleischer et al. | Innovative software solution for special data evaluation in mass spectrometry | |
CN108088929B (zh) | 一种左旋苯甘氨酸乙基邓钾盐的分析方法 | |
Chi et al. | Enantiomeric resolution, stereochemical assignment and toxicity evaluation of TPA enantiomers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Luzhou National High-tech Zone Pharmaceutical Industrial Park, Luzhou County, Luzhou City, Sichuan Province Patentee after: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. Country or region after: China Patentee after: Sichuan Keride Zhongling Food Co.,Ltd. Address before: 646100 Luzhou National High-tech Zone Pharmaceutical Industrial Park, Luzhou County, Luzhou City, Sichuan Province Patentee before: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: Sichuan Zhongling chuangtuo Pharmaceutical Technology Co.,Ltd. |